2013 Press Releases

Keyword Search
 
2017 | 2016 | 2015 | 2014 | 2013
December 10, 2013
Lorus Therapeutics Completes $7,001,500 Prospectus Offering of Common Shares
December 5, 2013
Lorus Therapeutics to Present at Oppenheimer & Co. 24th Annual Healthcare Conference
December 4, 2013
Lorus Therapeutics to File Final Prospectus for Equity Offering and Provides Corporate Update
December 2, 2013
Lorus Therapeutics Completes New Executive Management Team
November 22, 2013
Lorus Therapeutics Inc. Upsizes Overnight Marketed Financing to Approximately C$7,001,500 of Common Shares
November 21, 2013
Lorus Therapeutics Inc. Announces C$5,000,000 Overnight Marketed Financing
October 29, 2013
Lorus to Focus LOR-253 Development on AML Based on Genetic Insights Into the Causes of Certain Hematologic Cancers
October 28, 2013
Lorus Therapeutics Appoints New Chief Executive Officer
October 23, 2013
Lorus Therapeutics Postpones Annual Meeting Date
October 15, 2013
Lorus Therapeutics Reports First Quarter Results for Fiscal 2014
October 11, 2013
Lorus Therapeutics Apply to Extend Annual Meeting Date
October 1, 2013
Lorus Therapeutics Announces Presentation of its Phase I Clinical Trial of LOR-253 at the European Cancer Congress
September 26, 2013
Lorus Therapeutics Closes Private Placement
September 12, 2013
Lorus Therapeutics Board of Directors Announces Review of Strategic Alternatives
July 15, 2013
Lorus Therapeutics Reports Results for Fiscal Year 2013
July 9, 2013
Lorus Therapeutics Announces Promising Clinical Results for Anticancer Drug LOR-253
June 27, 2013
Lorus Therapeutics Appoints Dr. Brad Thompson, an Experienced Biotechnology Professional, to the Board of Directors
June 19, 2013
Lorus Therapeutics Closes Private Placement
April 17, 2013
Lorus Therapeutics Signs Research and License Option Agreement with Elanco
April 12, 2013
Lorus Therapeutics Reports Third Quarter Results for Fiscal Year 2013
March 5, 2013
Lorus Therapeutics Announces Allowance of Chinese Patent for Anticancer Drug LOR-253
February 12, 2013
Lorus Therapeutics to Present LOR-253 Data at 2013 AACR Annual Meeting
January 22, 2013
Lorus Therapeutics Announces Issuance of United States Patent for Cancer Therapy IL-17E
January 14, 2013
Lorus Therapeutics Reports Second Quarter Results for Fiscal Year 2013
January 7, 2013
Lorus Therapeutics Announces Successful Dose Escalation of Its Phase I Clinical Trial of LOR-253 and Initiation of a Biomarker Clinical Study in Cancer Patients